Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada
The primary objective of the study is to characterize the medical management of squamous cell carcinoma head and neck (SCCHN) patients diagnosed with recurrent/metastatic (R/M) disease (between 01July2013 and 30 June 2014) in the real-world setting.
Head and Neck Cancer
Best Therapy Response defined as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) based on physician's assessment for each therapy regimen, approximately 12 months|Overall Survival(OS) of patients with an Index diagnosis of R/M SCCHN, approximately 12 months|Progression-Free Survival(PFS) of patients with an Index diagnosis of R/M SCCHN, approximately 12 months|Recurrent-Free Survival(RFS) of patients with an Index diagnosis of R/M SCCHN, approximately 12 months|Overall Response Rate(ORR) of patients with an Index diagnosis of R/M SCCHN, approximately 12 months
Frequency of R/M SCCHN-related health care resource use, approximately 12 months|Treatment selection conditional on patient demographics, comorbidities, disease severity, and other characteristics as well as clinician demographics, therapy preferences, and other characteristics, approximately 12 months|Best Therapy Response conditional on patient demographics, comorbidities, disease severity, treatment received, and other characteristics, approximately 12 months
The primary objective of the study is to characterize the medical management of squamous cell carcinoma head and neck (SCCHN) patients diagnosed with recurrent/metastatic (R/M) disease (between 01July2013 and 30 June 2014) in the real-world setting.